Ambroxol acefyllinate

DB13141InvestigationalSmall molecule

Ambroxol acefyllinate is a bronchodilator indicated in the symptomatic treatment of bronchopulmonary disorders associated with bronchospasm. A medication used to treat disorders of the lungs and airways.

Chemical structure of Ambroxol acefyllinate
Mechanism
Curator reviewed
Formula / weight
C22H28Br2N6O5 · 616.311 g/mol (avg)
Also known as
Acebrophylline · Ambromucil · Ambroxol theophyllinacetate · Broncomnes · Surfolase
Code names
179118-73-1

Resolves to

Compound
UNII0HM1E174TNCAS96989-76-3ChEMBLCHEMBL4297663PubChem176595
Clinical / RWD
RxNorm236595
Structure
InChIKeyIPUHJDQWESJTGD-PFWPSKEQSA-NSMILESCN1C2=C(N(CC(O)=O)C=N2)C(=O)N(C)C1=O.NC1=C(Br)C=C(Br)C=C1CN[C@H]1CC[C@H](O)CC1
Targets
P14555PLA2G2A

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
6ContraindicationsEach with its own population and attribute set
Sign in
13Marketed productsAcross 1 country and 4 labellers
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ambroxol acefyllinate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In